Drug eases GVHD symptoms in patients who had stem cell transplant

12/1/2011 | U.S. News & World Report

Daily, low-dose injections of interleukin-2 eased symptoms of graft-versus-host disease, or GVHD, in cancer patients who underwent allogeneic hematopoietic stem cell transplantation, according to a study published in the New England Journal of Medicine. Of 23 patients given the drug for eight weeks, 12 showed improvement, according to the study.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC